抗体药物偶联物 (ADCs) 在实体瘤中的不断扩展领域：系统评价。
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
机构信息
Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center and Karolinska University Hospital, Stockholm, Sweden.
出版信息
Crit Rev Oncol Hematol. 2023 Dec;192:104189. doi: 10.1016/j.critrevonc.2023.104189. Epub 2023 Oct 21.
BACKGROUND
The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors.
METHODS
A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events.
RESULTS
A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing.
CONCLUSION
ADCs have shown promising results for several solid tumors and various cancer settings.
背景
靶向治疗的出现为获得更好的肿瘤学结果开辟了新途径。抗体药物偶联物（ADC）已成为不断扩展的靶向治疗时代的基石。本系统评价旨在描绘用于实体瘤的 ADC 的快速发展的临床前景。
方法
在 Medline、Embase 和 Cochrane 数据库中对 II 期和 III 期临床试验进行了文献检索。感兴趣的结果是客观缓解率、总生存期、无进展生存期和不良事件。
结果
共有 92 项临床试验（76 项 II 期和 16 项 III 期）评估了 ADC 对多种实体瘤的疗效和安全性。在 30 种研究的 ADC 中，有 8 种已获得监管机构对实体瘤的批准。目前，有 52 项 ADC 的 III 期临床试验正在进行中。
结论
ADC 已在多种实体瘤和多种癌症治疗环境中显示出良好的疗效。
Zotero 插件